2022-RA-631-ESGO The impact of COVID 19 on cervical cancer screening and triage. (20th October 2022)
- Record Type:
- Journal Article
- Title:
- 2022-RA-631-ESGO The impact of COVID 19 on cervical cancer screening and triage. (20th October 2022)
- Main Title:
- 2022-RA-631-ESGO The impact of COVID 19 on cervical cancer screening and triage
- Authors:
- Velasquez, Jessica M
Papatla, Katyayani
Kaplowitz, Elianna
Coughlin, Arielle C
Zachem, Alexis L
Goldberger, Cody
Blank, Stephianie V - Abstract:
- Abstract : Introduction/Background: Prior studies have demonstrated decreased rates of cervical cancer (CC) screening during the height of the COVID-19 pandemic. Delayed CC screening and management may increase incidence and mortality. This study examines the impact of the COVID-19 pandemic on rates of guideline-indicated colposcopy. Methodology: This study used retrospective data from a large, urban, academic institution-based clinic comprised of publicly-insured patients. Patients were non-pregnant, 21 to 65 years old without HIV or other immunocompromise. Three time periods were used: pre-COVID (pC) (3/1/2019–2/28/2020), COVID (C) (3/1/2020–2/28/2021), post-COVID vaccine (pv) (3/1/2021–2/28/2022). Primary outcomes were compared between groups using T-tests or Wilcoxon-Rank Sum tests for continuous measures and Chi-square or Fisher's exact tests for categorical measures. Results: N=486. The interval between pap smears significantly increased from a pC mean of 490 days, to a C mean of 607 days, to a pv mean of 670 days (p=0.0128). The proportion of patients who underwent guideline-indicated colposcopy did not differ significantly between time periods (p=0.0740). The interval between abnormal pap smear and colposcopy significantly decreased from 104 days pC (SD 69–188) to 67 days C (SD 42–147), to 57 days pv (SD 33–104) (p=0.0001). There were no significant differences in pap smear cytology, colposcopic pathology or rate of referral for excisional procedure over time. ThereAbstract : Introduction/Background: Prior studies have demonstrated decreased rates of cervical cancer (CC) screening during the height of the COVID-19 pandemic. Delayed CC screening and management may increase incidence and mortality. This study examines the impact of the COVID-19 pandemic on rates of guideline-indicated colposcopy. Methodology: This study used retrospective data from a large, urban, academic institution-based clinic comprised of publicly-insured patients. Patients were non-pregnant, 21 to 65 years old without HIV or other immunocompromise. Three time periods were used: pre-COVID (pC) (3/1/2019–2/28/2020), COVID (C) (3/1/2020–2/28/2021), post-COVID vaccine (pv) (3/1/2021–2/28/2022). Primary outcomes were compared between groups using T-tests or Wilcoxon-Rank Sum tests for continuous measures and Chi-square or Fisher's exact tests for categorical measures. Results: N=486. The interval between pap smears significantly increased from a pC mean of 490 days, to a C mean of 607 days, to a pv mean of 670 days (p=0.0128). The proportion of patients who underwent guideline-indicated colposcopy did not differ significantly between time periods (p=0.0740). The interval between abnormal pap smear and colposcopy significantly decreased from 104 days pC (SD 69–188) to 67 days C (SD 42–147), to 57 days pv (SD 33–104) (p=0.0001). There were no significant differences in pap smear cytology, colposcopic pathology or rate of referral for excisional procedure over time. There was a significant increase in the percentage of patients being contacted regarding abnormal pap smear results, specifically by by MD providers from 43% pC, to 53% C, to 61.6% pv (P=0.0029). Conclusion: This study demonstrates an increased interval between pap smears; however, those patients undergoing screening had significantly decreased time from pap to colposcopy which may be secondary to increased MD-to-patient telehealth communication and optimization of systems during the pandemic when routine clinics were limited. Future studies are needed to assess long-term outcomes of delayed CC screening on incidence and mortality. … (more)
- Is Part Of:
- International journal of gynecological cancer. Volume 32(2022)Supplement 2
- Journal:
- International journal of gynecological cancer
- Issue:
- Volume 32(2022)Supplement 2
- Issue Display:
- Volume 32, Issue 2 (2022)
- Year:
- 2022
- Volume:
- 32
- Issue:
- 2
- Issue Sort Value:
- 2022-0032-0002-0000
- Page Start:
- A374
- Page End:
- A375
- Publication Date:
- 2022-10-20
- Subjects:
- Generative organs, Female -- Cancer -- Periodicals
616.99465 - Journal URLs:
- http://journals.lww.com/ijgc/pages/default.aspx ↗
http://www3.interscience.wiley.com/journal/118544021/toc ↗
https://ijgc.bmj.com/ ↗
http://journals.lww.com ↗ - DOI:
- 10.1136/ijgc-2022-ESGO.803 ↗
- Languages:
- English
- ISSNs:
- 1048-891X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.273500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24562.xml